NEW YORK (GenomeWeb News) – Norwegian DNA analysis company iSentio today announced it has raised $1.5 million to grow its sales and marketing efforts and accelerate development of new application areas for its RipSeq software.
The funding was led by existing and new investors, including Norwegian seed capital fund, Sarsia Seed, a new investor.
In a statement, the company said that it has had a successful market introduction of its web-based sequence RipSeq software for identifying multiple bacteria after direct sequencing of clinical patient samples. The software is used in hospitals in both Europe and the US.
The new funding was to done to capitalize on the momentum from the launch and will allow the company to expand its presence and address new markets, iSentio CEO Bjarte Karlsen said in a statement.
iSentio also named a new board chairperson, Siri Fürst, who has held various managerial positions at Hafslund, Hafslund Nycomed, and Nycomed Pharma. She was also CEO of DiaGenic.